B16-F10 Metastatic Tumor Model Service for Melanoma

The B16-F10 metastatic tumor model for melanoma is a syngeneic preclinical in vivo platform in which highly metastatic murine melanoma cells colonize the lungs and other organs of immunocompetent mice, faithfully mirroring the hematogenous spread of malignant melanoma. Alfa Cytology offers comprehensive B16-F10 metastatic model services—from route selection and inoculation to longitudinal imaging, dosing, and histopathological endpoints—providing oncology teams with reproducible, high-quality data to accelerate the evaluation of anti-metastatic agents and immunotherapeutic strategies.

Overview of B16-F10 Metastatic Tumor Model for Melanoma

B16-F10 originates from the B16 melanoma, a spontaneous tumor that arose in the skin of a C57BL/6J mouse. Through Fidler's landmark in vivo selection strategy, cells recovered from lung metastatic colonies were serially re-inoculated into syngeneic mice across ten successive passages, progressively enriching for variants with superior lung-colonizing ability. The resulting B16-F10 subline displays a far higher metastatic potential than its parent B16-F0 and the once-selected B16-F1 line, and it retains the ability to form visible, melanin-pigmented (dark brown to black) tumor nodules—an intrinsic label that simplifies metastasis quantification. Genetically, B16 cells carry Braf and Met oncogene amplifications together with missense mutations in the Pten and Tp53 tumor suppressors, while B16-F10 exhibits low MHC class I expression and a suppressive tumor microenvironment, making it a challenging yet widely used system in experimental tumor immunology.

Fig 1. In vivo imaging of B16-F10 melanoma-bearing C57BL/6 mice: whole-body near-infrared/photographic imaging showing IR-780 probe accumulation in the primary tumor and spontaneous metastatic foci (including cranial and limb lesions) with radiance scale quantification (7.5×10³–1.8×10⁴), enabling noninvasive tracking of multi-organ metastatic dissemination beyond the lungs. (Salomão, Evelyn de Andrade, et al., 2023)

As a syngeneic model, B16-F10 grows in immunocompetent C57BL/6 hosts, so the full cascade of tumor-immune interactions is preserved—a decisive advantage over human xenografts when studying immunotherapy. The model can be deployed in two complementary formats: an experimental metastasis assay, in which tumor cells are injected directly into the circulation (most often via the lateral tail vein) so that they lodge in the pulmonary capillary bed and establish lung colonies within two to three weeks; and a spontaneous metastasis format, in which cells are implanted subcutaneously, intradermally, or in the footpad to form a primary tumor that subsequently disseminates. Tumor burden can be followed by bioluminescence imaging with luciferase-labeled cells or scored post-mortem by counting pigmented surface nodules, and tissues are further characterized by H&E histopathology and immunohistochemistry. Together, these features make the B16-F10 model a benchmark for studying melanoma metastasis, testing checkpoint inhibitors and vaccine strategies, and benchmarking small-molecule anti-metastatic compounds.

Cell Line Information: B16-F10

The table below summarizes the principal characteristics of the B16-F10 cell line most relevant to metastasis and immunotherapy research.

Our Services

With proven expertise in syngeneic melanoma modeling, Alfa Cytology provides fully customizable B16-F10 metastatic tumor model services that span the entire preclinical workflow—cell authentication, reporter labeling, host selection, inoculation through tail vein or other routes, in vivo imaging, treatment administration, and detailed metastasis quantification. Our scientists work closely with each client to align model parameters, endpoints, and timelines with the specific goals of the program.

Workflow of B16-F10 Metastatic Tumor Model Construction

Building a reliable B16-F10 metastatic model requires careful control at every stage, from cell quality to endpoint analysis. The workflow below describes how the model is constructed and evaluated in practice.

1. Cell line authentication and expansion: B16-F10 cells are verified by STR profiling and confirmed mycoplasma-negative, then expanded to the required scale with consistent viability for inoculation.
2. Reporter labeling (optional): Where longitudinal tracking is needed, cells are stably transduced with luciferase or fluorescent reporters; unlabeled cells are used when pigmented nodule counting is preferred.
3. Model format and route selection: The study design determines the format—tail vein injection for experimental lung metastasis, or subcutaneous/footpad/intradermal implantation for spontaneous metastasis—with matched host mice (typically 6- to 8-week-old C57BL/6).
4. Mouse preparation and inoculation: Mice are acclimated, randomized, and injected with B16-F10 cells (commonly 1×10⁵ to 2×10⁵ cells per mouse for intravenous routes) under sterile, ethically approved conditions.
5. Metastasis monitoring: Tumor burden is followed by in vivo bioluminescence imaging and/or by regular health assessment, with body weight recorded throughout the study.
6. Treatment phase: Once metastatic burden is established, animals are randomized to treatment and vehicle groups and dosed according to the client's regimen, including checkpoint inhibitors, vaccines, or targeted agents.
7. Endpoint analysis: At the study endpoint, lungs and other organs are collected; melanin-pigmented metastatic nodules are counted, and tissues are processed for H&E staining, immunohistochemistry, and molecular analyses.
8. Data analysis and reporting: Imaging time courses, nodule counts, and histology results are analyzed statistically and compiled into a comprehensive report to support candidate ranking and mechanism-of-action insights.

Fig 2. B16-F10 Metastatic Tumor Model construction workflow.

Case Study-B16-F10 Metastatic Tumor Model Development

Alfa Cytology routinely develops B16-F10 metastatic tumor models to support preclinical melanoma research programs. These models have been employed to assess the activity of candidate therapeutics against lung colonization, to compare treatment regimens with reference standards, and to explore immune-modulating approaches in a fully immunocompetent setting. Clients may request detailed case information and representative study data, which can be tailored to the specific questions and endpoints of each project.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a preclinical partner for B16-F10 metastatic melanoma studies through a combination of model proficiency, flexible study design, and attentive project support. Clients choose us because:

• Deep, hands-on experience with syngeneic melanoma models and their metastatic behavior.
• Flexible experimental and spontaneous metastasis formats, including tail vein, footpad, and intradermal routes.
• Optional luciferase or fluorescent labeling enabling non-invasive in vivo longitudinal monitoring.
• Strict cell line authentication and mycoplasma testing at every project stage.
• Customizable treatment arms, endpoint assays, and immunohistochemistry panels matched to your compound.
• Clear communication and on-schedule delivery of well-organized, decision-ready study reports.

Contact Us

Ready to move your melanoma program forward with a robust B16-F10 metastatic model? Contact us to discuss your study goals, and our team will propose a tailored design and timeline. Reach out today and put Alfa Cytology to work on generating the preclinical data your project needs.

For research use only. Not intended for any clinical use.